Balancing Risks and Rewards (Image Credits: Pixabay)
Purchase, N.Y. – PepsiCo leaders anticipate widespread use of GLP-1 weight-loss medications will reshape consumer habits, yet they view the trend as a catalyst for growth.
Balancing Risks and Rewards
During a February 3 conference call discussing fiscal 2025 results, CEO Ramon Laguarta described GLP-1 drugs – such as those from Novo Nordisk and Eli Lilly – as presenting both challenges and prospects. Consumers on these medications often experience reduced appetites, particularly for snacks. However, Laguarta emphasized a proactive stance. He stated, “I think there are more opportunities than threats, but there are both.” PepsiCo has prepared for broader adoption, especially as prices drop and pill forms gain approval.
The executive highlighted how families with GLP-1 users still participate in snacking, though in moderated amounts. This shift prompts PepsiCo to refine its portfolio without abandoning core categories. International markets also factor into the strategy, with similar trends emerging globally.
Portion Control Takes Center Stage
Seventy percent of PepsiCo’s U.S. food portfolio already consists of single-serve items, positioning the company well for smaller consumption patterns. Laguarta noted investments in capacity for 1-ounce and 1.5-ounce packs. Such formats address value-conscious shoppers while aligning with health goals.
Frito-Lay North America, despite recent volume declines, plans volume growth in 2026 after operational adjustments, including plant closures and SKU reductions. Price reductions of up to 15% on brands like Lay’s, Cheetos and Tostitos rolled out ahead of the Super Bowl. These moves aim to ease price friction and recapture demand.
Targeting Fiber, Hydration and Protein
PepsiCo accelerates innovation in nutrients sought by GLP-1 users. Fiber solutions include Pepsi Prebiotic cola and relaunches of Quaker cereals and SunChips with whole grains. Hydration products feature a refreshed Gatorade lineup and expanding Propel formats, which posted over 20% growth.
Protein remains a priority, with established lines like Muscle Milk – offering 26 grams in Base and 42 grams in Pro – joined by new entries. A Starbucks coffee packs 22 grams of protein and 5 grams of prebiotic fiber. Propel Protein Water combines electrolytes, protein and fiber. Laguarta called these “multiple vectors of transformation” pursued with urgency.
Acquisitions Fuel Expansion
Recent deals bolster PepsiCo’s health-focused lineup. The $1.2 billion acquisition of Siete Foods brings Mexican-American snacks to wider audiences. Poppi, bought for $300 million, adds prebiotic sodas. PepsiCo also deepened ties with Celsius Holdings via a $585 million stock purchase, owning 11%.
These investments target high-growth segments. Returns should accelerate in late 2026 as distribution integrates. Meanwhile, international volumes grew mid-single digits for 19 straight quarters outside North America.
Key Takeaways
- GLP-1s drive demand for portioned, nutrient-dense products over traditional snacks.
- Over 70% of U.S. foods already single-serve; innovations emphasize fiber, hydration, protein.
- Acquisitions and price adjustments position PepsiCo for 2026 recovery.
PepsiCo’s multifaceted approach transforms a potential headwind into a competitive edge, blending caution with bold innovation. What strategies do you see other food giants adopting in response? Share your thoughts in the comments.
